Clinic
New Hope Urgent Care-Pllc
New Hope Urgent Care-Pllc was paid $4.70M by Medicaid between Jan 2018 and Dec 2024, across 23 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 30% of everything it billed.
33Billing provider infoNEW HOPE URGENT CARE-PLLC
DURHAM, NC 27704
DURHAM, NC 27704
33aNPI1275839375assigned 02/07/2011
33bProvider typeUrgent Care Clinic/Center
28Total paid$4.70M
24GClaims107,426
24DCodes billed23
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in North Carolina
Rank by total paid#6 of 56
Median peer was paid$409K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,281 | $896K | |
| 2019 | 13,351 | $911K | |
| 2020 | 12,233 | $710K | |
| 2021 | 18,070 | $639K | |
| 2022 | 15,777 | $609K | |
| 2023 | 16,661 | $549K | |
| 2024incomplete | 15,053 | $382K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 30% | 22,060 | 14,499 | $1.43M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 30% | 28,627 | 18,497 | $1.40M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 24% | 24,083 | 15,268 | $1.10M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.2% | 8,423 | 5,621 | $340K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.4% | 1,215 | 938 | $114K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.7% | 1,618 | 1,039 | $81K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.4% | 897 | 616 | $68K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.0% | 2,497 | 1,716 | $47K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 2,215 | 1,621 | $36K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | <1% | 1,125 | 726 | $23K |
| 99199 | Unlisted special service, procedure or report | <1% | 11,490 | 10,460 | $21K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 803 | 497 | $19K |
11 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 438 | $10K |
| 99406 | <1% | 481 | $4K | |
| 96127 | <1% | 299 | $693.50 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 23 | $683.79 |
| 96160 | <1% | 310 | $377.73 | |
| 99441 | <1% | 22 | $374.16 | |
| 80305 | <1% | 295 | $253.14 | |
| 81003 | <1% | 147 | $166.59 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 28 | $142.59 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 15 | $141.30 |
| 99401 | 0% | 315 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSYED, ARJUMAND (MEDICAL DIRECTOR)